Article in MedComm, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Wenwen ZhaoShanghai Frontiers Science Center for Biomacromolecules and Precision Medicine Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology ShanghaiTech University Shanghai China.
Jifang LiShanghai Frontiers Science Center for Biomacromolecules and Precision Medicine Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology ShanghaiTech University Shanghai China.ORCID https://orcid.org/0000-0002-4083-6043
Xiao WangShanghai Frontiers Science Center for Biomacromolecules and Precision Medicine Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology ShanghaiTech University Shanghai China.
Wei XuKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) School of Basic Medical Sciences Fudan University Shanghai China.
Bao-Qing GaoShanghai Institute of Nutrition and Health University of Chinese Academy of Sciences Chinese Academy of Sciences Shanghai China.
Jiangchao XiangShanghai Frontiers Science Center for Biomacromolecules and Precision Medicine Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology ShanghaiTech University Shanghai China.
Yaofeng HouShanghai Frontiers Science Center for Biomacromolecules and Precision Medicine Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology ShanghaiTech University Shanghai China.
Wei LiuSchool of Physical Science and Technology ShanghaiTech University Shanghai China.
Jing WuShanghai Frontiers Science Center for Biomacromolecules and Precision Medicine Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology ShanghaiTech University Shanghai China.
Qilian QiShanghai Frontiers Science Center for Biomacromolecules and Precision Medicine Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology ShanghaiTech University Shanghai China.
Jia WeiCenter for Molecular Medicine Children's Hospital Fudan University Shanghai China.
Xiaoyu YangSchool of Physical Science and Technology ShanghaiTech University Shanghai China.
Lu LuKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) School of Basic Medical Sciences Fudan University Shanghai China.
Li YangCenter for Molecular Medicine Children's Hospital Fudan University Shanghai China.
Jia ChenShanghai Frontiers Science Center for Biomacromolecules and Precision Medicine Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology ShanghaiTech University Shanghai China.ORCID https://orcid.org/0000-0002-4242-2899
Bei YangShanghai Frontiers Science Center for Biomacromolecules and Precision Medicine Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology ShanghaiTech University Shanghai China.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
The spike protein of SARS-CoV-2 hijacks the host angiotensin converting enzyme 2 (ACE2) to meditate its entry and is the primary target for vaccine development. Nevertheless, SARS-CoV-2 keeps evolving and the latest Omicron subvariants BQ.1 and XBB have gained exceptional immune evasion potential through mutations in their spike proteins, leading to sharply reduced efficacy of current spike-focused vaccines and therapeutics. Compared with the fast-evolving spike protein, targeting host ACE2 offers an alternative antiviral strategy that is more resistant to viral evolution and can even provide broad prevention against SARS-CoV and HCoV-NL63. Here, we use prime editor (PE) to precisely edit
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Prime editor-mediated functional reshaping of · full record | OpenQuestion